A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis
Abstract Pyrazinamide (PZA) is an important first-line drug in all existing and new tuberculosis (TB) treatment regimens. PZA-resistance in M. tuberculosis is increasing, especially among M/XDR cases. Noted issues with PZA Drug Susceptibility Testing (DST) have driven the search for alternative test...
Main Authors: | S. M. Ramirez-Busby, T. C. Rodwell, L. Fink, D. Catanzaro, R. L. Jackson, M. Pettigrove, A. Catanzaro, F. Valafar |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2017-06-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-017-03452-y |
Similar Items
-
Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis
by: Wanliang Shi, et al.
Published: (2014-01-01) -
Gibbs Free Energy Calculation of Mutation in PncA and RpsA Associated With Pyrazinamide Resistance
by: Muhammad Tahir Khan, et al.
Published: (2020-04-01) -
Insight into novel clinical mutants of RpsA-S324F, E325K, and G341R of Mycobacterium tuberculosis associated with pyrazinamide resistance
by: Muhammad Tahir Khan, et al.
Published: (2018-01-01) -
Prognostic significance of novel katG mutations in Mycobacterium tuberculosis
by: F Valafar, et al.
Published: (2015-01-01) -
In Silico Drug Designing for ala438 Deleted Ribosomal Protein S1 (RpsA) on the Basis of the Active Compound Zrl15
by: Abdul Wadood, et al.
Published: (2021-12-01)